Holen Sie sich die Stockscreener-App
35.55
2.34%
-0.85
Alto Neuroscience Inc Aktie (ANRO) Neueste Nachrichten
HC Wainwright Issues Optimistic Forecast for ANRO Earnings - MarketBeat
H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $55 - Moomoo
H.C. Wainwright raises Alto Neuroscience price target to $55 - Investing.com
H.C. Wainwright raises Alto Neuroscience price target to $55 By Investing.com - Investing.com Canada
Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High on Analyst Upgrade - MarketBeat
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results - Stocktwits
HC Wainwright Increases Alto Neuroscience (NYSE:ANRO) Price Target to $55.00 - MarketBeat
Is Alto Neuroscience (ANRO) Fully Valued As ALTO 207 Expands With New Funding? - Sahm
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued? - Yahoo Finance
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline? - Yahoo Finance
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans - Yahoo Finance
Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding - Sahm
Alto Neuroscience (ANRO) Slips 0.5% as Stock Holds Above Key $30.53 SupportFund Manager Survey - vinanet.vn
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC) - The Globe and Mail
Alto Neuroscience (NYSE:ANRO) Upgraded to "Sell" at Wall Street Zen - MarketBeat
Alto Neuroscience (ANRO) investor group discloses 9.99% ownership cap - Stock Titan
Vestal Point Capital (ANRO) discloses 785,000-share Alto Neuroscience position in 13G/A - Stock Titan
BofA Securities Maintains Alto Neuroscience(ANRO.US) With Buy Rating - Moomoo
Alto Neuroscience (NYSE:ANRO) Stock Price Down 4.7%Here's Why - MarketBeat
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.56, Implies 16% Upside - TradingView
Sirenia Capital (ANRO) discloses 2.22M Alto Neuroscience shares under beneficial ownership - Stock Titan
BofA Adjusts Price Target on Alto Neuroscience to $37 From $33 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT) - The Globe and Mail
Alto Neuroscience stock hits all-time high at 32.74 USD By Investing.com - Investing.com Canada
Alto Neuroscience stock hits all-time high at 32.74 USD - Investing.com
Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Alto Neuroscience (NYSE:ANRO) Trading 8% Higher Following Earnings Beat - MarketBeat
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.11, Implies 27% Upside - TradingView
Wedbush Forecasts Strong Price Appreciation for Alto Neuroscience (NYSE:ANRO) Stock - MarketBeat
Alto Neuroscience (NYSE:ANRO) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
Biotech Stocks At 52-Week HighsBIVI +22%, XNCR, ANRO, HAE, ACAD - RTTNews
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $36.89, Implies 26% Upside - TradingView
ALTO NEUROSCIENCE INC : BTIG RAISES TARGET PRICE TO $37 FROM $28 - Bitget
Alto Neuroscience Q2 EPS beats estimates; completes $100M financing - scanx.trade
Alto Neuroscience (NYSE:ANRO) Announces Quarterly Earnings Results - MarketBeat
Alto Neuroscience (ANRO) boosts cash to $243.7M as R&D spend surges - stocktitan.net
Alto Neuroscience Reports Q2 Loss As ALTO-207 Program Expands - Quiver Quantitative
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Alto Neuroscience (NYSE:ANRO) Sets New 52-Week HighShould You Buy? - MarketBeat
Alto Neuroscience Escapes Investor Drug Trial Suit, For Now - Law360
Alto Neuroscience Inc (ANRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Shareholders SueWallSt in New Class Action Against Alto Neuroscience, Inc.Act Now - The National Law Review
Alto Neuroscience stock hits all-time high at 29.34 USD By Investing.com - Investing.com Australia
Alto Neuroscience (NYSE:ANRO) Sets New 12-Month HighShould You Buy? - MarketBeat
Alto Neuroscience stock hits all-time high at 29.34 USD - Investing.com
Alto Neuroscience (ANRO) Projected to Announce Earnings on Wednesday - MarketBeat
Alto Neuroscience (ANRO) Slips 0.71% as Shares Test Key Support ZoneUpthrust Pattern - Vinanet
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Alto Neuroscience, Inc. (ANRO) - The National Law Review
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications (ANRO) - Seeking Alpha
Perceptive Advisors LLC Buys 225,500 Shares of Alto Neuroscience, Inc. $ANRO - MarketBeat
Alto Neuroscience (NYSE:ANRO) Reaches New 52-Week HighWhat's Next? - MarketBeat
Eversept Partners LP Purchases New Position in Alto Neuroscience, Inc. $ANRO - MarketBeat
Alto Neuroscience Inc (ANRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ANRO|Alto Neuroscience Inc|Price:27.910|Chg%:+1.130 - TradingKey
BlackRock (ANRO) discloses 6.0% beneficial ownership in Alto Neuroscience common stock - Stock Titan
ANRO|Alto Neuroscience Inc|Price:27.350|Chg%:+0.570 - TradingKey
Alto Neuroscience Inc (ANRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alto Neuroscience Inc (ANRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alto Neuroscience Inc (ANRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Commodore Capital LP Has $61.22 Million Position in Alto Neuroscience, Inc. $ANRO - MarketBeat
Alto Neuroscience Inc (ANRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ANRO|Alto Neuroscience Inc|Price:26.780|Chg%:-0.080 - TradingKey
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):